New tool could help doctors decide who benefits from liver cancer surgery
NCT ID NCT06294808
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at over 1000 liver cancer patients who had surgery to remove their tumors. Researchers developed a model using tumor size, number of tumors, and a blood marker (AFP) to predict 5-year survival. They also compared outcomes between open and laparoscopic surgery, and between patients with viral vs. non-viral causes of liver cancer. The goal is to help doctors better select which patients are most likely to benefit from surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors more accurately predict which liver cancer patients will benefit most from surgery.
- What could go wrong
- This is a retrospective analysis, not a controlled trial, so the findings are observational and need validation in future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Centre, Singapore
Singapore, 168583, Singapore
-
Singapore General Hospital
Singapore, 169608, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.